← All trials
NCT05388487
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 16, 2022
- Primary completion
- Dec 31, 2022
- Completion date
- Jun 30, 2023
- First posted
- May 24, 2022
- Last posted
- May 27, 2022
- Enrollment
- 24
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- HighField Biopharmaceuticals CorporationLead sponsor
- Tigermed Consulting Co., LtdCollaborator
- Huashan Hospital ShanghaiOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.